Intelligent Investor
Sign up for free Sign up for free Sign up for free

IDT Australia Limited (ASX: IDT) - Share Price and Research

- Current share price for IDT : $0.105

IDT Australia Limited (IDT), an ASX-listed company, is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

IDT General Information +

ASX Code IDT
Website http://www.idtaus.com.au
Industry/Sector Pharmaceuticals
Market Cap ($M) 45
IDT Share Price $0.105
Day High $0.110
Day Low $0.105
Last Close $0.105
IDT Share Price Movement - ( No change )
Prices as at 16:41, 30 May 2025
+Security prices are delayed by at least 20 minutes and are indicative only.
Upsell Banner

IDT Related Research

IDT Australia Limited (IDT) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield
Interim 100% 12 Apr 2010 30 Apr 2010 $0.105 $0.098 -
Final 100% 2 Oct 2009 23 Oct 2009 $0.105 $0.098 -
Interim 5.5¢ 100% 6 Apr 2009 28 Apr 2009 $0.105 $0.098 -

See all dividends from IDT Australia Limited (IDT) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

IDT Australia Limited (IDT) price-sensitive announcements

IDT - New $3.2M Contract Supports Australia's Largest API Plant
IDT Australia Limited has secured a significant five-year manufacturing contract with Nacu
IDT Australia Limited (IDT)
9 Apr 2025 | 9:40 AM
IDT - 1HFY25 Results Presentation
IDT Australia Limited reported significant growth in its financial performance for the fir
IDT Australia Limited (IDT)
25 Feb 2025 | 9:41 AM
IDT - 1HFY25 Results
IDT Australia Limited has reported significant improvements in its financial performance f
IDT Australia Limited (IDT)
19 Feb 2025 | 9:18 AM
IDT - 1HFY25 Appendix 4D and Half Year Report
IDT Australia Limited reported its half-year results for the period ending December 31, 20
IDT Australia Limited (IDT)
19 Feb 2025 | 9:11 AM

See more price-sensitive ASX announcements or use our ASX Announcements tool to search for announcements across all ASX-listed securities.

IDT Australia Limited (IDT) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
IDT Australia Limited (IDT)
ORDINARY FULLY PAID
Health Care $45 Quarterly Revenue Growth of 30% with $62M in Open Proposals 29 Apr 2025 10:04AM $0.110 $0.105 fallen by 4.55%
IDT Australia Limited (IDT)
ORDINARY FULLY PAID
Health Care $45 Change of Director's Interest Notice - Geoffrey Sam 14 Apr 2025 9:17AM $0.100 $0.105 risen by 5%
IDT Australia Limited (IDT)
ORDINARY FULLY PAID
Health Care $45 New $3.2M Contract Supports Australia's Largest API Plant 9 Apr 2025 9:40AM $0.090 $0.105 risen by 16.67%
IDT Australia Limited (IDT)
ORDINARY FULLY PAID
Health Care $45 Notification of cessation of securities - IDT 4 Mar 2025 2:48PM $0.100 $0.105 risen by 5%
IDT Australia Limited (IDT)
ORDINARY FULLY PAID
Health Care $45 1HFY25 Results Presentation 25 Feb 2025 9:41AM $0.100 $0.105 risen by 5%
IDT Australia Limited (IDT)
ORDINARY FULLY PAID
Health Care $45 1HFY25 Results 19 Feb 2025 9:18AM $0.120 $0.105 fallen by 12.50%

IDT Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2024A -$5.41 -$1.60 -54.30% 0.00 0.00 0.00% 0.0%
2023A -$8.50 -$3.40 621.30% 0.00 0.00 0.00% 0.0%
2022A -$1.16 -$0.50 -154.70% 0.00 0.00 0.00% 0.0%

IDT Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2022 A 2023 A 2024 A 2022 A 2023 A 2024 A 2022 A 2023 A 2024 A
Botanix Pharmaceuticals Ltd (BOT) $745M 0.1646 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Clarity Pharmaceuticals Ltd (CU6) $691M 0.6392 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
IDT Australia Limited (IDT) $45M -0.5428 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Mayne Pharma Group Limited (MYX) $401M -0.4117 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Neuren Pharmaceuticals Limited (NEU) $1,729M -0.0957 -0.8435 2.5882 12.7152 81.2353 22.6393 0.00% 0.00% 0.00%

IDT Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 1.57 0.00
Market 0.23 13.60 1.09 0.91
Sector 1.01 19.90 2.04 2.16

IDT Directors

Name Position Start Date
Mr Geoffrey Joseph Sam Non-Executive Director 10 Oct 2022
Dr Jane Ryan Non-Executive Director 28 Jan 2022
Mr Mark Anthony Simari Non-Executive Director, Non-Executive Chairman 10 Oct 2022

IDT Australia Limited (IDT) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
10 Apr 2025 SAM, Geoffrey Buy Indirect Shares 228,015 $0.100 $22,801.500
9 Apr 2025 SAM, Geoffrey Buy Indirect Shares 20,617 $0.098 $2,020.470
21 Dec 2023 SAM, Geoffrey Buy Indirect Shares 78,720 $0.105 $8,265.600

See all changes in directors' interest & trades for IDT Australia Limited (IDT) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

IDT Management

Name Position
Paul Joseph Mcdonald Chief Executive Officer
Vasanthakumar Chief Financial Officer
Jim Sosic Chief Operating Officer
Nesci Commercial & Portfolio Director
Mark Andrew Licciardo Company Secretary
Marc Flanders Director of Commercial and Business Development
Paula Coutts Head of People & Safety
Priscilla Thiyageas Quality Director

IDT Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Neuren Pharmaceuticals Limited (IDT). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
48,283,127 (11.43%) One Managed Invt Funds Ltd
37,840,996 (8.96%) HSBC Custody Nominees (Australia) Limited
29,043,707 (6.88%) One Funds Management Limited
23,125,664 (5.47%) Ubs Nominees Pty Ltd

IDT Calendar of Events

Date Event
24 February 2026 Report (Interim)
18 February 2026 Report (Interim)
25 August 2025 Report (Annual)
25 August 2025 Report (Prelim)

FAQs about Neuren Pharmaceuticals Limited (IDT)

Neuren Pharmaceuticals Limited's (IDT) current share price is $0.11. This constitutes a price movement of 7.14% when compared to the share price 7 days ago and is -22.22% below IDT's 12-month high of $0.14 per share. Prices are delayed by at least 20 minutes.

Relative to the previous close share price of $0.11, Neuren Pharmaceuticals Limited's (IDT) current share price of $0.11 constitutes a movement of or 0%. Neuren Pharmaceuticals Limited's (IDT) share price movement is 7.14% when compared to 7 days ago and is -22.22% below IDT's 52-week high of $0.14.

Neuren Pharmaceuticals Limited's (IDT) 52-week high is $0.14 which was reached on 30 Jul 2024. Relative to this, IDT's current share price of $0.11 constitutes a -$0.03 or -22.22% drop since that high of $0.14 per IDT share.

Neuren Pharmaceuticals Limited's (IDT) 52-week low is $0.08 which was reached on 7 Apr 2025. Relative to this, IDT's current share price of $0.11 constitutes a $0.02 or 25% gain since that low of $0.08 per IDT share.

Over the last 12 months, Neuren Pharmaceuticals Limited (IDT) has a daily average trading volume of 238,251 IDT shares per day.

Neuren Pharmaceuticals Limited (IDT) has a current dividend yield of n/a this year. Last year's dividend yield was 0%. The dividend yield for IDT is a ratio that tells you the percentage of Neuren Pharmaceuticals Limited's (IDT) share price that it pays out in dividends each year.

Neuren Pharmaceuticals Limited (IDT) last dividend payment was $0.01 per share and was paid on 30 Apr 2010. This last IDT dividend included 100% franking.

Neuren Pharmaceuticals Limited (IDT) will release its next Annual Report on 25 August 2025. Neuren Pharmaceuticals Limited's (IDT) last annual report was released on 26 Aug 2024. Click here to view Neuren Pharmaceuticals Limited's (IDT) last annual report.

Neuren Pharmaceuticals Limited (IDT) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), ResMed Inc. (RMD), Sigma Healthcare Limited (SIG), and Pro Medicus Limited (PME).

The price-to-earnings (P/E) ratio for Neuren Pharmaceuticals Limited (IDT) is 0. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of Neuren Pharmaceuticals Limited's (IDT) share price to its earnings per IDT share.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.